Iovance Biotherapeutics (NASDAQ:IOVA) Issues Quarterly Earnings Results

Iovance Biotherapeutics (NASDAQ:IOVA) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04, FiscalAI reports. The business had revenue of $121.47 million for the quarter, compared to the consensus estimate of $115.98 million. Iovance Biotherapeutics had a negative net margin of 58.20% and a negative return on equity of 29.71%. Iovance Biotherapeutics’s revenue for the quarter was up 64.8% on a year-over-year basis.

Here are the key takeaways from Iovance Biotherapeutics’ conference call:

• Iovance reported record third-quarter revenue of approximately $122 million, up 80% year over year, including about $102 million from AMTAGVI; it reaffirmed 2026 revenue guidance of $410 million–$420 million. The company has treated more than 1,000 commercial patients and expects at least 110 authorized treatment centers by year-end.
• Gross margin reached a record 60%, operating expenses were managed tightly, and Iovance ended the quarter with approximately $382 million in cash, which it expects to fund operations well into 2029. Management said it is moving toward profitability but did not provide a timeline.
• In previously treated non-squamous metastatic lung cancer, lifileucel showed a 24.6% response rate among 69 patients; a biomarker-enriched subgroup had a 59.1% response rate. Iovance plans an sBLA submission in 2027 and is starting a prospective biomarker-selected study, though the findings remain investigational.
• Updated soft tissue sarcoma results showed a 55.6% response rate in five of nine patients with UPS or DDLPS, including two responses ongoing beyond a year. The registrational SARATOGA trial is enrolling, with submissions planned for 2028 or 2029.
• In a phase II frontline melanoma cohort, lifileucel plus pembrolizumab produced a 62.5% response rate, including complete responses in 29.2% of patients; median overall survival had not been reached after more than four years of follow-up. The phase III TILVANCE-301 trial is enrolling to support a potential frontline approval.

Iovance Biotherapeutics Stock Performance

Shares of NASDAQ:IOVA opened at $8.04 on Monday. The company has a 50 day moving average of $11.37 and a 200 day moving average of $5.97. The stock has a market cap of $3.64 billion, a P/E ratio of -15.17 and a beta of 0.88. Iovance Biotherapeutics has a 12 month low of $2.08 and a 12 month high of $15.37.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. UBS Group lifted their price objective on shares of Iovance Biotherapeutics from $7.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday, November 3rd. The Goldman Sachs Group started coverage on Iovance Biotherapeutics in a report on Thursday, September 24th. They issued a “buy” rating and a $15.00 price target for the company. Barclays lifted their price target on Iovance Biotherapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Friday. Citizens Jmp lifted their price target on Iovance Biotherapeutics from $8.00 to $12.00 and gave the company a “market outperform” rating in a research report on Friday. Finally, Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $13.80.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
• Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
• Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
• Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook

About Iovance Biotherapeutics

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient.

The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.